Literature DB >> 28256104

Haemodynamic Influences of Bisoprolol in Hypertensive Middle-Aged Men: A Double-Blind, Randomized, Placebo-Controlled Cross-Over Study.

Lauri Suojanen1, Antti Haring1, Antti Tikkakoski1, Jenni K Koskela1, Anna M Tahvanainen1, Heini Huhtala2, Mika Kähönen1,3, Kalle Sipilä3, Arttu Eräranta1, Jukka T Mustonen1,4, Kari Kivistö1, Ilkka H Pörsti1,4.   

Abstract

Treatment with beta-blockers appears to show inferior reduction in central versus peripheral blood pressure. We aimed to examine simultaneous changes in central and peripheral blood pressure, vascular resistance, cardiac function and arterial stiffness during beta-blockade. Haemodynamics were investigated after 3 weeks of bisoprolol treatment (5 mg/day) in a double-blind, randomized, placebo-controlled cross-over trial in never-treated 16 Caucasian males with grade I-II primary hypertension using continuous tonometric pulse wave analysis and whole-body impedance cardiography. Bisoprolol decreased radial (134/80 versus 144/89 mmHg) and aortic blood pressure (122/80 versus 130/90 mmHg) and heart rate (57 versus 68 beats/min) when compared with placebo (p < 0.05 for all). Ejection duration (336 versus 316 ms) and stroke volume (109 versus 98 ml) were increased (p < 0.01 for all), while cardiac output was not significantly changed (6.2 versus 6.6 l/min). Bisoprolol decreased pulse wave velocity (7.8 versus 8.9 m/s, p < 0.001), but after adjustment for blood pressure, the decrease was not significant (8.16 versus 8.52 m/s, p = 0.464). The treatment reduced pulse pressure amplification from central to peripheral circulation (30 versus 38%, p = 0.002). No differences were observed in systemic vascular resistance, augmentation index, aortic characteristic impedance or total arterial stiffness after bisoprolol versus placebo. Bisoprolol decreased central and peripheral blood pressure and pulse wave velocity in male individuals with grade I to grade II hypertension. The decrease in pulse wave velocity was related to the antihypertensive effect. Reduced pulse pressure amplification indicates that peripheral blood pressure was reduced more efficiently than central blood pressure.
© 2017 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28256104     DOI: 10.1111/bcpt.12771

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  4 in total

1.  Central blood pressure for the management of hypertension: Is it a practical clinical tool in current practice?

Authors:  Hao-Min Cheng; Shao-Yuan Chuang; Tzung-Dau Wang; Kazuomi Kario; Peera Buranakitjaroen; Yook-Chin Chia; Romeo Divinagracia; Satoshi Hoshide; Huynh Van Minh; Jennifer Nailes; Sungha Park; Jinho Shin; Saulat Siddique; Jorge Sison; Arieska Ann Soenarta; Guru Prasad Sogunuru; Apichard Sukonthasarn; Jam Chin Tay; Boon Wee Teo; Yuda Turana; Narsingh Verma; Yuqing Zhang; Ji-Guang Wang; Chen-Huan Chen
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-12-16       Impact factor: 3.738

2.  Adverse influence of bisoprolol on central blood pressure in the upright position: a double-blind placebo-controlled cross-over study.

Authors:  Lauri Suojanen; Antti Haring; Antti Tikkakoski; Heini Huhtala; Mika Kähönen; Arttu Eräranta; Jukka T Mustonen; Ilkka H Pörsti
Journal:  J Hum Hypertens       Date:  2019-03-18       Impact factor: 3.012

3.  Resting heart rate control and prognosis in coronary artery disease patients with hypertension previously treated with bisoprolol: a sub-group analysis of the BISO-CAD study.

Authors:  Yun-Dai Chen; Xin-Chun Yang; Vinh Nguyen Pham; Shi-An Huang; Guo-Sheng Fu; Xiao-Ping Chen; Binh Quang Truong; Yu Yang; Shao-Wen Liu; Tian-Rong Ma; Dong-Soo Kim; Tae-Hoon Kim
Journal:  Chin Med J (Engl)       Date:  2020-05-20       Impact factor: 2.628

4.  Diurnal changes in central blood pressure and pulse pressure amplification in patients with obstructive sleep apnoea.

Authors:  Yasmina Serinel; Camilla Hoyos; Ahmad Qasem; Brendon J Yee; Ronald R Grunstein; Keith H Wong; Craig L Phillips
Journal:  Int J Cardiol Hypertens       Date:  2019-04-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.